Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dalotuzumab + MK-2206
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Dalotuzumab + MK-2206 is a combination therapy investigated in oncology, comprised of **dalotuzumab**, a humanized monoclonal antibody targeting Insulin-like growth factor 1 receptor (IGF-1R), and **MK-2206**, an orally administered small molecule allosteric inhibitor of AKT isoforms (AKT1, AKT2, AKT3). This dual-agent regimen aims to exert vertical pathway inhibition, targeting both upstream (IGF-1R) and downstream (AKT) drivers of cancer cell proliferation, survival, and resistance mechanisms. It has been studied in phase I trials for advanced solid tumors, notably ovarian cancer and colorectal cancer with biomarker-driven populations. The rationale for this combination is that blockade of both IGF-1R and PI3K/AKT/mTOR pathways provides synergistic anti-tumor activity and may help overcome resistance to anti-IGF-1R therapies[1][5].
- Other names
- dalotuzumab + MK-2206
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AKT2 (Rac-beta serine/threonine-protein kinase)AKT3 (RAC-gamma serine/threonine-protein kinase)IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on dalotuzumab + MK-2206.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dalotuzumab + MK-2206.